Tasly pharma secures drug registration for Wenjing granules

Tasly Pharmaceutical Group Co., Ltd. recently obtained a drug registration certificate from the National Medical Products Administration for its Wenjing Tang Granules, officially designated with approval number C20250013 and certificate number 2025S03004. This marks the product's official approval for market launch following regulatory review.

The Wenjing Tang Granules, classified as a Class 3.1 traditional Chinese medicine, are formulated based on a classic ancient recipe. They are intended to treat conditions arising from "blood stasis due to cold in the sea of blood" and "qi-blood stagnation syndrome," presenting symptoms like irregular menstruation and abdominal pain. The company has invested 10,715,500 yuan in the research and development of this product.

Currently, Tasly is one of three manufacturers in China to hold a drug registration certificate for Wenjing Tang Granules. The company has commenced pre-production preparations and anticipates the drug's production and sales will be influenced by various factors. Investors are advised to exercise caution due to market uncertainties.